share price, page-4

Thymus,

I am hoping that long term, Nedcarro is not far off the mark with his/her sp prediction. It may seem far off at present but if we get CE mark approval and the product is half as good as we believe it to be, sales will indeed take a large chunk of market share for available ulcer treatments.

If there are indeed a number of doctors, hospitals and specialists waiting to access this product, we may be onto something huge. Time will tell but if all falls into place the sp IMO should reach something like Nedcarro predicted with time.


Any other sp predictions would be welcome based on the assumption that TIS get the nod and Vitrogro performs as expected (way ahead of the pack). One would have to guess $1.00 - $1.50 or so after approval is not too much of a stretch.

Surfrat